Silo Pharma Explores Ibogaine-Based Therapeutics for TBI
Silo Pharma announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury and associated neuropsychiatric conditions. Silo has filed a provisional patent application with the United States Patent and Trademark Office titled "Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine." The invention applies to the use of ibogaine and related compounds for the treatment of TBI, post-traumatic stress disorder and associated conditions.
